TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04727437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment
Description: Withholding anticoagulation for at least 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: anticoagulation drug given for at least 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: direct oral anticoagulants
Description: anticoagulation drug given for at least 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low molecular weight heparin
Description: anticoagulation drug, subcutaneous injection given for at least 3 months.
Study: NCT05496322

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Non Invasive Blood Pressure Monitoring
Description: Intermittent non-invasive arterial pressure monitoring
Study: NCT05739968

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care + oncology case manager (OCM) care
Description: Usual care + oncology case manager (OCM) care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-domains Active-living Program (MAP) with e-health enhanced intervention + usual care + oncology case manager (OCM) care
Description: Multi-domains Active-living Program (MAP) with e-health enhanced intervention + usual care + oncology case manager (OCM) care
Study: NCT06127238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-1898 tablets
Description: Supplied as 5 mg and 40 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-1898 tablets
Description: Supplied as 5 mg and 40 mg tablets
Study: NCT06611059

Intervention type: DEVICE
Intervention: PSG
Description: Two replicas of each scapula are made. The scapulae are drilled with a commercial guide and with an in-house guide separately
Study: NCT05589519

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Partial rehabilitation using PEEK
Description: A 3-unit implant-supported fixed prosthesis using PEEK polymer in its composition delivered as definitive prosthesis for partial rehabilitation of edentulous jaws.
Study: NCT05690373

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic effect on influenza vaccine response
Description: Seroconversion rate: the percentage of subjects achieving at least a 4-fold increase or an increase from \>10 to 40 in Ab titre for seronegative subjects.
Study: NCT06676501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ExAblate
Description: Transcranial focused ultrasound thalamotomy
Study: NCT04411303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step length biofeedback
Description: Participants will be provided with visual feedback of their right and left step lengths on a screen in front of a treadmill.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Propulsive force biofeedback
Description: Participants will be provided with real-time visual feedback of anterior-posterior ground reaction forces of the paretic limb during stance phase on a screen in front of a treadmill.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interlimb asymmetry biofeedback
Description: Participants will be provided with visual feedback of stride-by-stride values of their interlimb asymmetry on a screen in front of a treadmill.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic intensity-based walking
Description: Participants will walk at three different aerobic intensities. Aerobic intensity will be set based on target heart rate zones calculated with the Karvonen Formula. For low intensity, participants will walk at 30-40% intensity. In moderate intensity conditions, participants will walk at a 50-60% intensity level. In vigorous intensity conditions, participants will walk at an 70-80% intensity level. Aerobic intensity will be manipulated by changing walking speed.
Study: NCT06677398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Debriefing Method 1
Description: The researchers used a debriefing method that they chose after a virtual simulation

Intervention type: OTHER
Group type: OTHER
Intervention: Debriefing Method VP
Description: The researchers used the debriefing method that virtual patient simulator presents

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Debriefing Method 2
Description: The researchers used a debriefing method that they chose after a virtual simulation
Study: NCT06677476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile application training
Description: Researchers compiled literature information and used their expertise to create mobile application content. This content will be downloaded to mobile phones via mobile application software and participants will be trained.
Study: NCT06677229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan HBr 40 mg
Description: Oral administration of Eletriptan HBr in the form of tablets, 40 mg once daily (q.d.) for a total of 6 days, together with their usual SOC treatment.
Study: NCT06192953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Proprioceptive Stimulation
Description: Orthoses with a system of 12 stimulators producing mechanical oscillations are attached to the joints of the upper limbs (wrist, elbow and shoulder) or lower limb joints (ankle, knee, hip). These stimulators, which are all synchronized, deliver mechanical oscillations (FPS) that give the illusion of complex movements, while the patient is bedridden, neither moving nor producing effort.
Study: NCT06251219

Intervention type: DIAGNOSTIC_TEST
Intervention: PCR
Description: PCR test for EV71, CA16, CA10, or CA6
Study: NCT03889600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REDD-CAT
Description: After obtaining informed consent from a participant and gathering baseline data, the study RA will send a flag in the EMR to notify the nurse care manager that a patient has enrolled in the REDD-CAT pilot. The nurse care manager will then incorporate the administration of the REDD-CAT to the patient as part of standard care discharge planning. He or she will utilize the REDD-CAT results report as a guideline for generating appropriate referrals to address unmet social needs identified.
Study: NCT05727085

Intervention type: OTHER
Intervention: All pregnant women with a twin pregnancy and the offspring
Description: No intervention
Study: NCT05391334

Intervention type: DEVICE
Intervention: Qumea
Description: Contactless motion sensor (Qumea®) for bed-exit detection in combination with Qumea fall detection.
Study: NCT05223491

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: En Bloc resection
Description: Tumour is resected and removed from the bladder in one piece, if possible.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional TURB
Description: Tumour is resected piecemeal.
Study: NCT05637437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer supported diabetes self-care intervention
Description: Participants in the intervention group will attend a multi-faceted 8 weeks peer supported diabetes self-care intervention through digital communication.~* Weekly group video telephony meeting facilitated by trained peer supporters.~* Support and assistance through instant messaging services between peer supporters and participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants in the control group will receive the usual care of the hospital.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Participants in the control group will receive the usual care of the hospital.
Study: NCT04208126

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECMO
Description: ECMO implantation immediately after ICU admission
Study: NCT05294419

Intervention type: DEVICE
Group type: OTHER
Intervention: CVD Integrated Risk Test
Description: CVD IRT (IVD regulations with a software device)
Study: NCT05069155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamification
Description: Each participant signs a pre-commitment contract agreeing to try their best to achieve their daily step goal. Each week over the 12 week intervention period, participants are endowed 70 points (10/day). Participants are informed they will lose 10 points for each day the step goal is not met. Points are replenished at the start of the week. At the end of the week, if the participant has 40 points or more, he/she will advance one level, or drop one level if they have less than 40 points. The levels include: blue (lowest), bronze, silver, gold, platinum (highest). Each participant begins in the middle (silver). Each participant will also select a spouse, family member, or friend that they see often to serve as a supportive sponsor that receives a weekly email participants progress including points, game level, and average step countThis supportive sponsor will help to enhance social incentives to motivate the individual towards his or her goal.
Study: NCT05032521

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: collection of biological data
Description: collection of biological data

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: collection of biological data
Description: collection of biological data

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: collection of demographic, ventilatory, cardiac echocardiography, arterial and venous gas data
Description: These data are usually measured continuously (monitoring of the resuscitation patient) and recorded on recorded on the resuscitation software.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: collection of demographic, ventilatory, cardiac echocardiography, arterial and venous gas data
Description: These data are usually measured continuously (monitoring of the resuscitation patient) and recorded on recorded on the resuscitation software.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: usual management based on the use of drugs according to international recommendations

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stratified treatment according to algorithm
Description: management based on arteriovenous CO2 gradient Stratification of drug use
Study: NCT05690373

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic effect on influenza vaccine response
Description: Seroconversion rate: the percentage of subjects achieving at least a 4-fold increase or an increase from \>10 to 40 in Ab titre for seronegative subjects.
Study: NCT04741932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dementia Care Management (DCM)
Description: A computerized Information and Care Management System (IMS) will identify unmet nursing, medical, psychosocial and social needs of the PwD and its informal caregiver. Based on this data, the IMS generates suggestions for interventions: The DCM in cooperation with the general practitioner (GP) develops an individual treatment and care plan that is tailored to the needs of the PwD and its caregiver. The DCM will initiate the implementation of respective actions and monitor the status of implementation. Therefore, the DCMs are supposed to take on activities that were previously usually performed by doctors (redistribution of tasks between physicians and qualified nurses in primary care).
Study: NCT04258852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low strength nicotine e-liquid
Description: Low strength nicotine e-liquid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low strength nicotine e-liquid
Description: Low strength nicotine e-liquid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High strength nicotine e-liquid
Description: High strength nicotine e-liquid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High strength nicotine e-liquid
Description: High strength nicotine e-liquid
Study: NCT04859998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dog-assisted therapy
Description: It will consist of 20 sessions conducted twice a week in the facilities of the association. It will involve different activities and physical exercises facilitated by the dogs. The program will be conducted in two associations (12 participants in each one, 6 belonging to the experimental and 6 belonging to the control group in each association) and in groups of three participants.
Study: NCT06084663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg Tablets
Description: Each film-coated tablet contains 30 mg of apremilast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apremilast 30 mg Tablets
Description: Each film-coated tablet contains 30 mg of apremilast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otezla 30 mg film-coated tablets
Description: Each film-coated tablet contains 30 mg of apremilast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Otezla 30 mg film-coated tablets
Description: Each film-coated tablet contains 30 mg of apremilast
Study: NCT04959903

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic T cell progenitors, cultured ex-vivo
Description: Injection of T cell progenitors at \[Day 4-Day 10\] after T cell depleted allogeneic HSCT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic T cell progenitors, cultured ex-vivo
Description: Injection of T cell progenitors at \[Day 4-Day 10\] after T cell depleted allogeneic HSCT
Study: NCT05009095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Listening Program® with bone conduction headphones
Description: The Listening Program method of Music-Based Auditory Stimulation is enhanced with the addition of bone conduction technology with the ABT Bone Conduction System. Bone Conduction combines the experience of listening to music through modified headphones adding subtle, synchronized acoustic vibration of the skin and skeletal system, engaging the whole body and brain in the listening process. This multi-sensory approach accelerates and expands the benefits of The Listening Program.
Study: NCT06235294

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Daily capsule of 200 mg Polygonum cuspidatum (Solgar®, Dietimport, Lisboa, Portugal) yielding 100 mg/day resveratrol (trans-3,5,4'-trihydroxystilbene), by morning, every day during the 3 months preceding in vitro fertilization treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid
Description: Daily capsule of 400 mcg folic acid (Solgar®, Dietimport, Lisboa, Portugal), by morning, every day during the 3 months preceding in vitro fertilization treatment.
Study: NCT04921293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: A diet with \<50gr of carbohydrates per day. Monosaturated fats consumption will encourage over saturated fats

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Exogenous ketones
Description: Administration of ketone monoester 25 ml t.i.d

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard diet + placebo
Description: A standard diet incorporating current recommendations (low in sodium and low in liquids) for heart failure patients.
Study: NCT04925336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nociceptive stimulation
Description: These investigations in healthy volunteers will study the association between cerebral and neurovegetative (sympathetic and parasympathetic) electrophysiological responses in response to a controlled and tolerable pain stimulus, determined for each individual. The pain stimulus will be delivered using an electrically conductive glove used in clinical practice for transcutaneous therapeutic stimulation.~The thresholds of nociception and tolerance will be determined in each healthy volunteer.
Study: NCT06394726

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise İntervention
Description: Aerobic and Core Stabilization Exercise Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise İntervention
Description: Aerobic and Core Stabilization Exercise Intervention
Study: NCT04778293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diacutaneous fibrolysis
Description: An experienced physiotherapist in the diacutaneous fibrolysis technique will apply the treatment to the lower limb, previously randomized, in the following musculature and intermuscular septums: quadratus lumbar, gluteus maixum, biceps femoris and semitendinosus. Intervention procedure will last about 10-15 minutes
Study: NCT05081921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MesoCellA-Ortho administration
Description: Single dose of MesoCellA-Ortho product consisting of 20 mln of autologous adipose tissue-derived mesenchymal stem/ stromal cells (AT-MSCs) will be administrated intraarticularly in patients enrolled in MesoCellA-Ortho- treated groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MesoCellA-Ortho administration
Description: Single dose of MesoCellA-Ortho product consisting of 20 mln of autologous adipose tissue-derived mesenchymal stem/ stromal cells (AT-MSCs) will be administrated intraarticularly in patients enrolled in MesoCellA-Ortho- treated groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MesoCellA-Ortho administration
Description: Single dose of MesoCellA-Ortho product consisting of 20 mln of autologous adipose tissue-derived mesenchymal stem/ stromal cells (AT-MSCs) will be administrated intraarticularly in patients enrolled in MesoCellA-Ortho- treated groups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HA administration
Description: Single dose of hyaluronic acid (HA) will be administrated intraarticularly as an active control in patients enrolled in Control Patients groups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HA administration
Description: Single dose of hyaluronic acid (HA) will be administrated intraarticularly as an active control in patients enrolled in Control Patients groups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HA administration
Description: Single dose of hyaluronic acid (HA) will be administrated intraarticularly as an active control in patients enrolled in Control Patients groups.
Study: NCT05405868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinomide
Description: Nicotinamide tablets (750mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo
Study: NCT05783193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGIR (Traditional Gastrointestinal Remedy)
Description: TGIR botanical formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT04918758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Purastat Arm
Description: Generic name of device and principal intended use(s):~Still PuraStat from a CE mark perspective. PuraStat is an aqueous self-assembling peptide solution of 2.5% concentration RADA16~Indication for use:~PuraStat is indicated for haemostasis in the following situations encountered during surgery, when haemostasis by ligation or standard means is insufficient or impractical:~* Bleeding from small blood vessels and oozing from capillaries of the parenchyma of solid organs. Oozing from vascular anastomoses~* Bleeding from small blood vessels and oozing from capillaries of the GI tract following surgical procedures~* Reduction of delayed bleeding following gastrointestinal endoscopic submucosal dissection (ESD) procedures in the colon.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard Care Arm
Description: Sucralfate enemas 2g twice daily for 8 weeks, this is standard care in patients with haemorrhagic radiation proctopathy in the short term
Study: NCT06355492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality goggles (VR )
Description: Patients will take buccal infiltration anaethesia using (Virtual reality goggles) that properly adjusted around the patient's head and in front of his/her eyes.
Study: NCT05191342

Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme-linked immunosorbent assay for PCSK9
Description: Enzyme-linked immunosorbent assay for plasma PCSK9
Study: NCT06355492

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: regular screen
Description: Patients will take buccal infiltration anaethesia using (regular screen ).
Study: NCT05834842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unisalud
Description: The UNISALUD intervention will be made up of 42 videos, made using the visual collage technique, where illustration, video fragments and visual interactions are mixed and in some there will be a presenter to achieve captivating visual material. to the participant. Likewise, it will be accompanied by digital infographics that will help reinforce the information proposed by the intervention.
Study: NCT05346523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isabel Pro - The DDx generator (CDDS)
Description: Isabel Pro - the DDx generator is a software developped for health professionals with the intention to support them in broadening their differential diagnoses. After the first patient examination, the resident is asked to enter patient symptoms into Isabel Pro, which returns a list of possible diagnoses from its underlying database that matches the entered data. The diagnosing resident physicians will be asked to consult Isabel Pro at least once within the first hour after the first patient assessement. After entering patient symptoms into the software, Isabel Pro will itself return a list with possible diagnoses derived from their underlying database. It is then free to the physician to decide whether one or more of the suggested DDx should be considered for further diagnostic or treatment procedure based on clinical judgement.
Study: NCT06322797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Stimulation was performed using a biphasic stimulator (ALTMS® Remed, Republic of Korea) and a 70-mm figure-eight coil. The routine stimulation procedure is described as follows. First, the resting motor threshold was measured for each patient. At the lowest stimulus output, a stimulus was applied to the M1 cortex of the uninjured hemisphere aiming at the site that caused the largest visible twitch in the participant's thumb. The resting motor threshold was defined as the intensity required to generate a motor-induced potential of \> 50 uV in the contralateral abductor pollicis brevis muscle at least 5 out of 10 times with 30 s of inter-stimulus time interval.~Stimulation was given at 100% of the resting motor threshold stimulator output: 20 Hz, 5-s train duration, 55-s inter-train interval, and a total number of stimulations of 2000 pulses per session for 20 min.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Stimulation was performed using a biphasic stimulator (ALTMS® Remed, Republic of Korea) and a 70-mm figure-eight coil. The routine stimulation procedure is described as follows. After identifying the brain site that is activated during finger tapping during fMI, Stimulation was given at 100% of the resting motor threshold stimulator output: 20 Hz, 5-s train duration, 55-s inter-train interval, and a total number of stimulations of 2000 pulses per session for 20 min. the resting motor threshold was measured for each patient at target brain site.